Loetitia Favre

Loetitia Favre

Auto-generated profile, based on publicly available information

Loetitia Favre

Department of Pathology AP‐HP, Henri Mondor University Hospital Creteil France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CNCong Trung Nguyen
Cong Trung Nguyen
SCStefano Caruso
Stefano Caruso
PMPascale Maille
Pascale Maille
ABAurélie Beaufrère
Aurélie Beaufrère
JAJeremy Augustin
Jeremy Augustin
JCJulien Calderaro
Julien Calderaro
Purpose: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare malignancy associated with an overall poor prognosis. We aimed to investigate the immune profile of cHCC-CCA and determine its impact on disease outcome. Experimental Design: We performed a multicenter study of 96 patients with cHCC-CCA. Gene expression profile was analyzed using nCounter PanCancer IO 360 Panel. Densities of main immune cells subsets were quantified from digital slides of IHC stainings. Genetic alterations were investigated using targeted next-generation sequencing. Results: Two main immune subtypes of cHCC-CCA were identified by clustering analysis: an “immune-high” (IH) subtype (57% of the cases) and an “immune-low” (IL) subtype (43% of the cases). Tumors classified as IH showed overexpression of genes related to immune cells recruitment, adaptive and innate immunity, antigen presentation, cytotoxicity, immune suppression, and inflammation (P < 0.0001). IH cHCC-CCAs also displayed activation of gene signatures recently shown to be associated with response to immunotherapy in patients with HCC. Quantification of immunostainings confirmed that IH tumors were also characterized by higher densities of immune cells. Immune subtypes were not associated with any genetic alterations. Finally, multivariate analysis showed that the IH subtype was an independent predictor of improved overall survival. Conclusions: We have identified a subgroup of cHCC-CCA that displays features of an ongoing intratumor immune response, along with an activation of gene signatures predictive of response to immunotherapy in HCC. This tumor subclass is associated with an improved clinical outcome. These findings suggest that a subset of patients with cHCC-CCA may benefit from immunomodulating therapeutic approaches.

1 January 2014 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TSThouraya Ben Safta
Thouraya Ben Safta
LZLinda Ziani
Linda Ziani
LFLoetitia Favre
Loetitia Favre
LLLucille Lamendour
Lucille Lamendour
GGGwendoline Gros
Gwendoline Gros
JTJerome THIERY
Jerome THIERY
Granzyme B (GzmB) plays a major role in CTLs and NK cell–mediated elimination of virus-infected cells and tumors. Human GzmB preferentially induces target cell apoptosis by cleaving the proapoptotic Bcl-2 family member Bid, which, together with Bax, induces mitochondrial outer membrane permeabilization. We previously showed that GzmB also induces a rapid accumulation of the tumor-suppressor protein p53 within target cells, which seems to be involved in GzmB-induced apoptosis. In this article, we show that GzmB-activated p53 accumulates on target cell mitochondria and interacts with Bcl-2. This interaction prevents Bcl-2 inhibitory effect on both Bax and GzmB-truncated Bid, and promotes GzmB-induced mitochondrial outer membrane permeabilization. Consequently, blocking p53–Bcl-2 interaction decreases GzmB-induced Bax activation, cytochrome c release from mitochondria, and subsequent effector caspases activation leading to a decreased sensitivity of target cells to both GzmB and CTL/NK-mediated cell death. Together, our results define p53 as a new important player in the GzmB apoptotic signaling pathway and in CTL/NK-induced apoptosis.

17 August 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJulien Calderaro
Julien Calderaro
Luca Di TommasoLuca Di Tommaso
Luca Di Tommaso
PMPascale Maillé
Pascale Maillé
ABAurélie Beaufrère
Aurélie Beaufrère
CNCong Trung Nguyen
Cong Trung Nguyen
SCStefano Caruso
Stefano Caruso

13 November 2015 in Autophagy
Verified
Journal Article
Open access
APAnais Pujals
Anais Pujals
LFLoëtitia Favre
Loëtitia Favre
CPCatherine Pioche-Durieu
Catherine Pioche-Durieu
ARAude Robert
Aude Robert
GMGuillaume Meurice
Guillaume Meurice
Joëlle WielsJoëlle Wiels
Joëlle Wiels
The Epstein-Barr virus (EBV) is associated with various lymphoproliferative disorders and lymphomas. We have previously demonstrated that treating wild-type TP53-expressing B cell lines with the TP53 pathway activator nutlin-3 induced apoptosis in EBV-negative and EBV-positive latency I cells whereas EBV-positive latency III cells remained much more apoptosis-resistant. Here, we report a constitutively high level of autophagy in these resistant cells which express high levels of the proautophagic protein BECN1/Beclin 1 based, at least in part, on the activation of the NFKB signaling pathway by the viral protein LMP1. Following treatment with nutlin-3, several autophagy-stimulating genes were upregulated both in EBV-negative and EBV-positive latency III cells. However the process of autophagy was only triggered in the latter and was associated with an upregulation of SESN1/sestrin 1 and inhibition of MTOR more rapid than in EBV-negative cells. A treatment with chloroquine, an inhibitor of autophagy, potentiated the apoptotic effect of nutlin-3, particularly in those EBV-positive cells which were resistant to apoptosis induced by nutlin-3 alone, thereby showing that autophagy participates in this resistant phenotype. Finally, using immunohistochemical staining, clinical samples from various B cell lymphoproliferations with the EBV-positive latency II or III phenotype were found to harbor a constitutively active autophagy.

1 March 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAlma Abou Samra
Alma Abou Samra
ARAude Robert
Aude Robert
CGCrystal Gov
Crystal Gov
LFLoëtitia Favre
Loëtitia Favre
LELaure Eloy
Laure Eloy
FRFanny Roussi
Fanny Roussi

1 November 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SDSandy Desrat
Sandy Desrat
APAnais Pujals
Anais Pujals
CCClaire Colas
Claire Colas
JDJérémy Dardenne
Jérémy Dardenne
CGCharlotte Gény
Charlotte Gény
FRFanny Roussi
Fanny Roussi